CY1122007T1 - Μορια δεσμευσης-ang2 - Google Patents
Μορια δεσμευσης-ang2Info
- Publication number
- CY1122007T1 CY1122007T1 CY20191100625T CY191100625T CY1122007T1 CY 1122007 T1 CY1122007 T1 CY 1122007T1 CY 20191100625 T CY20191100625 T CY 20191100625T CY 191100625 T CY191100625 T CY 191100625T CY 1122007 T1 CY1122007 T1 CY 1122007T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ang2
- binding molecules
- same
- binding
- vhhs
- Prior art date
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 4
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162615 | 2012-03-30 | ||
| EP13718796.9A EP2831111B1 (en) | 2012-03-30 | 2013-03-27 | Ang2-binding molecules |
| PCT/EP2013/056635 WO2013144266A1 (en) | 2012-03-30 | 2013-03-27 | Ang2-binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122007T1 true CY1122007T1 (el) | 2020-10-14 |
Family
ID=48190468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100625T CY1122007T1 (el) | 2012-03-30 | 2019-06-18 | Μορια δεσμευσης-ang2 |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20130259859A1 (enExample) |
| EP (1) | EP2831111B1 (enExample) |
| JP (1) | JP5970734B2 (enExample) |
| KR (1) | KR102020255B1 (enExample) |
| CN (1) | CN104321344B (enExample) |
| AU (1) | AU2013241769B2 (enExample) |
| BR (1) | BR112014023415B1 (enExample) |
| CA (1) | CA2865464C (enExample) |
| CL (1) | CL2014002393A1 (enExample) |
| CY (1) | CY1122007T1 (enExample) |
| DK (1) | DK2831111T3 (enExample) |
| EA (1) | EA031182B1 (enExample) |
| ES (1) | ES2729165T3 (enExample) |
| HR (1) | HRP20190817T1 (enExample) |
| HU (1) | HUE044263T2 (enExample) |
| IL (1) | IL234234B (enExample) |
| IN (1) | IN2014DN06904A (enExample) |
| LT (1) | LT2831111T (enExample) |
| MX (1) | MX350248B (enExample) |
| NZ (1) | NZ628584A (enExample) |
| PH (1) | PH12014502179B1 (enExample) |
| PL (1) | PL2831111T3 (enExample) |
| PT (1) | PT2831111T (enExample) |
| RS (1) | RS58732B1 (enExample) |
| SI (1) | SI2831111T1 (enExample) |
| TR (1) | TR201908638T4 (enExample) |
| WO (1) | WO2013144266A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| JP2017532342A (ja) | 2014-10-17 | 2017-11-02 | アムジエン・インコーポレーテツド | 眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体 |
| WO2016156466A1 (en) * | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| EP3328886B1 (en) * | 2015-07-29 | 2020-09-16 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
| CA3040194A1 (en) * | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
| KR102143132B1 (ko) * | 2016-12-26 | 2020-08-10 | 기초과학연구원 | 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물 |
| US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
| KR20200013231A (ko) * | 2017-06-02 | 2020-02-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 항암 조합 요법 |
| CN108659130B (zh) * | 2018-05-28 | 2021-09-10 | 长春力太生物技术有限公司 | 一种抗癌胚抗原纳米抗体及其应用 |
| CN112739717B (zh) | 2018-06-29 | 2025-02-11 | 璟尚生物制药公司 | 三特异性拮抗剂 |
| CN113728004A (zh) * | 2019-02-25 | 2021-11-30 | 药物抗体公司 | 抗Ang2抗体及其用途 |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| CN114340735B (zh) | 2019-06-28 | 2024-11-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
| JP2023516392A (ja) * | 2020-03-03 | 2023-04-19 | アプティテュード メディカル システムズ、インコーポレイテッド | アプタマーおよびその使用 |
| CN111875706B (zh) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | 一种抗人IgE蛋白的单域抗体及其应用 |
| WO2022256820A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
| CN118251412A (zh) * | 2021-09-10 | 2024-06-25 | 海南康哲维盛科技有限公司 | 抗ang2抗体及其制备方法和应用 |
| EP4596579A1 (en) | 2022-09-28 | 2025-08-06 | Kexing Biopharm Co., Ltd. | Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2 |
| CN115819592A (zh) * | 2022-12-27 | 2023-03-21 | 上海医药集团生物治疗技术有限公司 | 靶向ror1的抗原结合蛋白 |
| WO2025117641A2 (en) * | 2023-12-01 | 2025-06-05 | Tavotek Biotherapeutics (Hong Kong) Limited | ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF |
| WO2025137089A1 (en) * | 2023-12-19 | 2025-06-26 | Beam Therapeutics Inc. | Cd19-binding polypeptides, compositions comprising the same, and methods for use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| MXPA03006358A (es) | 2001-01-17 | 2004-12-02 | Trubion Pharmaceuticals Inc | Proteinas de fusion dominio de enlace-inmunoglobulina. |
| ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| WO2005044858A1 (en) | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| WO2004041867A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
| KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| CA2678218A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| WO2009109635A2 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| HUE042053T2 (hu) * | 2008-06-05 | 2019-06-28 | Ablynx Nv | Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére |
| CA2746395C (en) * | 2008-12-10 | 2019-07-09 | Ablynx N.V. | Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
-
2013
- 2013-03-27 JP JP2015502346A patent/JP5970734B2/ja active Active
- 2013-03-27 AU AU2013241769A patent/AU2013241769B2/en not_active Ceased
- 2013-03-27 PT PT13718796T patent/PT2831111T/pt unknown
- 2013-03-27 MX MX2014011171A patent/MX350248B/es active IP Right Grant
- 2013-03-27 KR KR1020147028419A patent/KR102020255B1/ko active Active
- 2013-03-27 BR BR112014023415-9A patent/BR112014023415B1/pt not_active IP Right Cessation
- 2013-03-27 EP EP13718796.9A patent/EP2831111B1/en active Active
- 2013-03-27 PL PL13718796T patent/PL2831111T3/pl unknown
- 2013-03-27 DK DK13718796.9T patent/DK2831111T3/en active
- 2013-03-27 CN CN201380026471.3A patent/CN104321344B/zh active Active
- 2013-03-27 RS RS20190627A patent/RS58732B1/sr unknown
- 2013-03-27 HU HUE13718796 patent/HUE044263T2/hu unknown
- 2013-03-27 WO PCT/EP2013/056635 patent/WO2013144266A1/en not_active Ceased
- 2013-03-27 TR TR2019/08638T patent/TR201908638T4/tr unknown
- 2013-03-27 IN IN6904DEN2014 patent/IN2014DN06904A/en unknown
- 2013-03-27 LT LTEP13718796.9T patent/LT2831111T/lt unknown
- 2013-03-27 CA CA2865464A patent/CA2865464C/en active Active
- 2013-03-27 ES ES13718796T patent/ES2729165T3/es active Active
- 2013-03-27 HR HRP20190817TT patent/HRP20190817T1/hr unknown
- 2013-03-27 NZ NZ628584A patent/NZ628584A/en not_active IP Right Cessation
- 2013-03-27 EA EA201401065A patent/EA031182B1/ru not_active IP Right Cessation
- 2013-03-27 SI SI201331449T patent/SI2831111T1/sl unknown
- 2013-03-28 US US13/852,402 patent/US20130259859A1/en not_active Abandoned
-
2014
- 2014-08-21 IL IL234234A patent/IL234234B/en active IP Right Grant
- 2014-09-10 CL CL2014002393A patent/CL2014002393A1/es unknown
- 2014-09-29 PH PH12014502179A patent/PH12014502179B1/en unknown
-
2016
- 2016-12-21 US US15/386,181 patent/US20170107281A1/en not_active Abandoned
-
2018
- 2018-07-02 US US16/025,067 patent/US20190135907A1/en not_active Abandoned
-
2019
- 2019-06-18 CY CY20191100625T patent/CY1122007T1/el unknown
-
2020
- 2020-03-13 US US16/817,700 patent/US20200207845A1/en not_active Abandoned
-
2023
- 2023-03-17 US US18/185,493 patent/US20230203146A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122007T1 (el) | Μορια δεσμευσης-ang2 | |
| CY1118339T1 (el) | Διειδικα μορια προσδεσης που προσδενονται στον vegf και στην ang2 | |
| EA201300311A1 (ru) | Vegf-связывающие молекулы | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| IN2012DN02752A (enExample) | ||
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
| EA201301109A1 (ru) | БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Dll4 И Ang2 | |
| EA201591898A1 (ru) | Антитела, направленные на m-csf |